Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

S'inscrire

MIRA MIRA Pharmaceuticals Inc

0,6869

-0,0231 (-3,25%)

Après les heures de négociation

Dernière mise à jour : 22:22:01

Retardé de 15 minutes

Form EFFECT - Notice of Effectiveness

MIRA Pharmaceuticals (NASDAQ:MIRA)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024

Plus de graphiques de la Bourse MIRA Pharmaceuticals

MIRA Pharmaceuticals (NASDAQ:MIRA)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024

Plus de graphiques de la Bourse MIRA Pharmaceuticals

Actualités MIRA Pharmaceuticals Inc

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing
Lundi 24 Juin 2024 ( il y a 2 jours) • PR Newswire (US)

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
Lundi 10 Juin 2024 ( il y a 2 semaines) • PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities
Vendredi 31 Mai 2024 ( il y a 4 semaines) • Edgar (US Regulatory)

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
Mercredi 29 Mai 2024 ( il y a 4 semaines) • PR Newswire (US)

Form 8-K - Current report
Mercredi 29 Mai 2024 ( il y a 4 semaines) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Mercredi 22 Mai 2024 ( il y a 1 mois) • Edgar (US Regulatory)

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
Mardi 21 Mai 2024 ( il y a 1 mois) • PR Newswire (US)

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
Lundi 20 Mai 2024 ( il y a 1 mois) • PR Newswire (US)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Lundi 13 Mai 2024 ( il y a 1 mois) • Edgar (US Regulatory)

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
Mardi 2 Avril 2024 ( il y a 3 mois) • PR Newswire (US)

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
Jeudi 21 Mars 2024 ( il y a 3 mois) • PR Newswire (US)

Form 8-K - Current report
Jeudi 7 Mars 2024 ( il y a 4 mois) • Edgar (US Regulatory)

Plus d'articles sur MIRA Pharmaceuticals Inc

PANATLANTICA PN

Delayed Upgrade Clock

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales